H-CYTE, Inc. (HCYT)
| Market Cap | 6.12M |
| Revenue (ttm) | 1.61M |
| Net Income (ttm) | -4.80M |
| Shares Out | 255.09M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,000 |
| Open | 0.0240 |
| Previous Close | 0.0240 |
| Day's Range | 0.0240 - 0.0240 |
| 52-Week Range | 0.0100 - 0.2890 |
| Beta | 1.35 |
| Analysts | Sell |
| Price Target | n/a |
| Earnings Date | May 11, 2022 |
About HCYT
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
Financial Performance
In 2021, H-CYTE's revenue was $1.61 million, a decrease of -25.07% compared to the previous year's $2.15 million. Losses were -$4.80 million, -25.70% less than in 2020.
Financial StatementsNews
H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise
Proceeds to Support Inorganic Growth and General Working Capital Purposes Proceeds to Support Inorganic Growth and General Working Capital Purposes
H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.
Targets one of Healthcare's Largest Multi-Billion Dollar Markets: Cardiac Electrophysiology Targets one of Healthcare's Largest Multi-Billion Dollar Markets: Cardiac Electrophysiology